Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination With Ezabenlimab (BI 754091) in Solid Tumors

NCT04147234 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04147234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04147234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, First in Human Trial Evaluating BI 1387446 Alone and in Combination With Ezabenlimab (BI 754091) in Solid Tumors
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
August 3, 2020
Completion date
March 21, 2024
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms